| abstract |
The presently disclosed subject matter provides that blockade of CCR2 alone or CCR2 and CCR5 together improves thymic recovery and thymic immune function and treats or prevents graft versus host disease ("GVHD") and organ transplant rejection. Accordingly, the disclosed subject matter provides methods for increasing thymic recovery or thymic function in a subject, e.g., a human subject, by administering to the subject an effective amount of a CCR2 antagonist, a CCR5 antagonist and a CCR2 antagonist, or a dual CCR2/CCR5 antagonist. The presently disclosed subject matter also provides methods for treating, inhibiting, or preventing GVHD or organ transplant rejection in a subject, e.g., a human subject, by administering to the subject an effective amount of a CCR2 antagonist alone, a CCR5 antagonist and a CCR2 antagonist, or a dual CCR2/CCR5 antagonist. |